| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10910816 | Lung Cancer | 2015 | 6 Pages |
Abstract
KRAS mutated NSCLC patients treated with taxane-based chemotherapy had best ORR. Response to chemotherapy regimens was different in types of KRAS mutation. Especially patients with G12V had better response to taxane treatment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Wouter W. Mellema, Lucie Masen-Poos, Egbert F. Smit, Lizza E.L. Hendriks, Joachim G. Aerts, Arien Termeer, Martijn J. Goosens, Hans J.M. Smit, Michel M. van den Heuvel, Anthonie J. van der Wekken, Gerarda J.M. Herder, Frans H. Krouwels, Jos A. Stigt,